
-
Toulouse crush Toulon to reach Top 14 semis as Castres pay tribute to Raisuqe
-
Marseille, Monaco clinch Champions League qualification from Ligue 1
-
'One of those days': Atletico record-breaker Sorloth hits four
-
Toulouse's Ntamack suffers concussion in Top 14, Willemse nears exit
-
Record-breaker Sorloth hits four as Atletico smash Real Sociedad
-
'Weight off my shoulders': Bayern's Kane toasts breakthrough title
-
Sinner grateful for 'amazing' support on Italian Open return from doping ban
-
Hamburg return to Bundesliga after seven-year absence
-
Toulouse's Ntamack suffers concussion in Top 14 clash
-
India, Pakistan reach ceasefire -- but trade claims of violations
-
'Long time coming': Bayern's Kane toasts breakthrough title
-
US, China conclude first day of trade talks in Geneva
-
Kane tastes first title as champions Bayern bid farewell to Mueller
-
Benfica deny Sporting to take Portuguese title race to wire
-
Sinner makes triumphant return from doping ban at Italian Open
-
Sinner wins at Italian Open in first match since doping ban
-
Leo XIV, new pope and 'humble servant of God', visits Francis's tomb
-
India claims Pakistan violated truce, says it is retaliating
-
Champions League race hots up as Man City held, Villa win
-
Kane tastes first title as champions Bayern see off Mueller
-
US envoy calls enrichment 'red line' ahead of new Iran talks
-
Hastoy lifts La Rochelle as Castres pay tribute to Raisuqe
-
Southampton avoid Premier League 'worst-ever' tag with Man City draw
-
Injury forces Saints quarterback Carr to retire
-
S.Korea conservative party reinstates candidate after day of turmoil
-
Verdict due Tuesday in Depardieu sexual assault trial
-
Man City held by Southampton as Brentford, Brighton win
-
Groundbreaking Cameroonian curator Kouoh dies: Cape Town art museum
-
Leo XIV, 'humble servant of God', visits sanctuary in first papal outing
-
Leipzig miss Champions League as Bochum and Kiel relegated
-
Tarling wins Giro time trial in Tirana, Roglic in pink
-
US and China meet in 'important step' towards de-escalating trade war
-
Champions Chelsea finish WSL season unbeaten
-
At his former US university, the new pope is just 'Bob'
-
Ukraine allies set ultimatum to Russia for 30-day ceasefire
-
Deja vu in France as Marc Marquez beats brother Alex in MotoGP sprint
-
Alonso has 'every door open': Real Madrid's Ancelotti
-
Swiatek's Rome title defence ends early as Sinner set for hero's return
-
Marc Marquez wins French MotoGP sprint race
-
Swiatek's Italian Open title defence ended early by Collins
-
Uproar as S. Korea conservatives switch presidential candidate
-
Vollering retains women's Vuelta title in style
-
India and Pakistan agree to ceasefire after days of attacks
-
Pope Leo XIV says choice of name reflects social commitment
-
Ecuador declares national mourning for 11 troops killed by guerrillas
-
Thousands in Spain confined indoors for hours by toxic fumes
-
Postecoglou 'hopeful' Son will return for Spurs against Palace
-
Ukraine, Europe allies seek 30-day Russia truce starting Monday
-
Flick wants 'dominant' Barca in vital Liga Clasico
-
Panicked Indians flee Kashmir city on special train

Court to hear lawsuit seeking to ban abortion pill in US
A Texas judge favored by anti-abortion activists will hear arguments Wednesday in an unprecedented challenge to the legality of a widely-used abortion pill.
US District Court Judge Matthew Kacsmaryk announced Monday the hearing on a lawsuit alleging the US Food and Drug Administration (FDA) should never have approved the "dangerous" prescription drug Mifepristone in 2000.
Mifepristone, one component of a two-drug regimen used for medication abortion, has been used by an estimated 5.6 million women to terminate pregnancies since its approval, according to the FDA.
It is can be used in the United States up to 10 weeks of pregnancy.
The pro-abortion rights Guttmacher Institute estimates that more than half of all abortions involve the use of mifepristone.
But the Alliance Defending Freedom, a Christian advocacy group, sued the FDA saying its approval "disavow(ed)" science, "ignored" potential health impacts and "disregarded" the complications that can arise with using mifepristone.
"The FDA failed America's women and girls when it chose politics over science and approved chemical abortion drugs for use in the United States," they said.
Galvanized by the Supreme Court's ruling in June that overturned the constitutional right to an abortion, abortion opponents have now set their sights on obtaining prohibitions on mifepristone.
Already the treatment has been halted in some 15 states which have banned all abortion since the 2022 Supreme Court decision.
The Texas suit seeks to block it nationally by overturning the FDA's approval of the drug.
The FDA has urged the judge to reject the request.
"The public interest would be dramatically harmed by effectively withdrawing from the marketplace a safe and effective drug that has lawfully been on the market for 22 years," it said.
Kacsmaryk was targeted by the plaintiffs to hear the case due to his deep conservative Christian beliefs and previous anti-abortion stance.
He had been expected since February 24 to issue a ruling in the case, which asks him to suspend the FDA's approval of the drug while the lawsuit proceeds.
Apparently fearing protestors descending on the courthouse in Amarillo, Texas, Kacsmaryk originally sought to keep the hearing secret until the last minute, but it leaked to media.
If he does order the suspension, it could leave pregnant women with the alternative of using only misoprostol, the second pill in the medication abortion treatment.
But using misoprostol alone is more physically traumatic than the two-pill procedure, and some fear doctors might be unwilling to prescribe it alone.
If mifepristone is banned, "access to medication abortion would end across the country -- even in those states where abortion rights are protected," the Center for Reproductive Rights said.
A.Jones--AMWN